Alaunos Therapeutics, Inc.
TCRT
$2.63
-$0.05-1.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.00K | 6.00K | 6.00K | 6.00K | 5.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.00K | 6.00K | 6.00K | 6.00K | 5.00K |
| Cost of Revenue | 363.00K | 1.38M | 4.90M | 9.90M | 16.28M |
| Gross Profit | -354.00K | -1.38M | -4.89M | -9.90M | -16.27M |
| SG&A Expenses | 4.46M | 6.04M | 8.61M | 10.67M | 12.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.82M | 7.42M | 13.51M | 20.57M | 28.50M |
| Operating Income | -4.81M | -7.42M | -13.50M | -20.56M | -28.49M |
| Income Before Tax | -4.68M | -11.78M | -19.13M | -26.77M | -35.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.68 | -11.78 | -19.13 | -26.77 | -35.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.68M | -11.78M | -19.13M | -26.77M | -35.14M |
| EBIT | -4.81M | -7.42M | -13.50M | -20.56M | -28.49M |
| EBITDA | -4.81M | -7.17M | -12.58M | -18.94M | -26.18M |
| EPS Basic | -2.92 | -7.36 | -11.95 | -16.73 | -21.97 |
| Normalized Basic EPS | -1.83 | -2.81 | -5.12 | -8.20 | -11.48 |
| EPS Diluted | -2.92 | -7.36 | -11.95 | -16.73 | -21.97 |
| Normalized Diluted EPS | -1.83 | -2.81 | -5.12 | -8.20 | -11.48 |
| Average Basic Shares Outstanding | 6.41M | 6.41M | 6.40M | 6.40M | 6.40M |
| Average Diluted Shares Outstanding | 6.41M | 6.41M | 6.40M | 6.40M | 6.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |